SBIR Phase I: Membrane Protein Microarrays

SBIR 第一阶段：膜蛋白微阵列

• 批准号: 0318938
• 负责人: Athena Guo
• 金额: $ 10万
• 依托单位: MICROSURFACES INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2004-04-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0318938&HistoricalAwards=false
• 关键词: SBIR; Phase; Membrane; Protein; Microarrays

This Small Business Innovation Research (SBIR) Phase I project is to develop chemical strategies for the fabrication of membrane protein microarrays. Membrane proteins are important to many aspects of biomedical research because a major percentage of drug targets are membrane bound. Thus, the ability to fabricate membrane protein arrays will greatly aid the drug discovery process. In principle, the success of a membrane protein array requires two critical ingredients: (1) the membrane must be immobilized on a solid surface with sufficient robustness to survive repeated contacts with liquid environment under physiological conditions ; and (2) protein molecules must be present in the membrane environment with sufficient membrane mobility to ensure their activity. The fine balance between these two factors requires the understanding and development of necessary surface chemistry. This Phase I project will demonstrate that such a balance could be achieved by controlling the electrostatic interaction between the supported membrane and the solid surface. The research is centered around this hypothesis and includes two specific aims: (1) to develop robust lipid membrane bilayers supported on a solid surface based on electrostatic interactions , and (2) to immobilize membrane proteins and demonstrate their functions in protein-ligand interactions using a model system: opioid receptors.The commercial application of this project is in the area of membrane protein microarray technology. The technology is expected to accelerate efforts aimed at drug discovery and development.

这项小型企业创新研究（SBIR）I期项目是为制造膜蛋白微阵列的化学策略。 膜蛋白对生物医学研究的许多方面很重要，因为很大一部分药物靶标是膜结合的。 因此，制造膜蛋白阵列的能力将极大地帮助药物发现过程。 原则上，膜蛋白阵列的成功需要两种关键成分：（1）必须将膜固定在固体表面上，具有足够的稳健性，以在生理条件下与液体环境的重复接触； （2）蛋白质分子必须存在于膜环境中，并具有足够的膜迁移率以确保其活性。 这两个因素之间的良好平衡需要理解和发展必要的表面化学。 该阶段I项目将证明可以通过控制受支持的膜和固体表面之间的静电相互作用来实现这种平衡。该研究集中在该假设围绕该假设围绕：（1）开发基于静电相互作用的固体表面上支持的坚固脂质膜双层，以及（2）将膜蛋白固定并证明其在蛋白质 - 素体相互作用中的功能，使用模型系统：epioid受体。预计该技术将加速针对药物发现和开发的努力。